Rezolute, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RZLT research report →
About the company
Rezolute, Inc. , a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism.
- CEO
- Nevan Charles Elam
- IPO
- 2013
- Employees
- 74
- HQ
- Redwood City, CA, US
Price Chart
- Market Cap
- $472.80M
- P/E
- -5.99
- P/S
- 0.00
- P/B
- 4.37
- EV/EBITDA
- -5.68
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -58.82%
- ROIC
- -73.68%
- Revenue
- $0 · 0.00%
- Net Income
- $-74,412,000 · -8.70%
- EPS
- $-0.98 · 26.32%
- Op Income
- $-79,894,000
- FCF YoY
- -20.41%
- 52W High
- $11.46
- 52W Low
- $1.07
- 50D MA
- $3.84
- 200D MA
- $5.09
- Beta
- 0.55
- Avg Volume
- 1.85M
Get TickerSpark's AI analysis on RZLT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 30, 26 | Evans Daron | buy | 10,000 |
| Mar 2, 26 | ROBERTS BRIAN KENNETH | other | 11,439 |
| Mar 2, 26 | Evans Daron | other | 11,438 |
| Mar 2, 26 | Elam Nevan C | other | 27,618 |
| Dec 16, 25 | Hogenhuis Wladimir | buy | 5,650 |
| Dec 16, 25 | ROBERTS BRIAN KENNETH | buy | 28,000 |
| Dec 15, 25 | Evans Daron | buy | 40,000 |
| Dec 15, 25 | Evans Daron | buy | 2,500 |
| Dec 15, 25 | Evans Daron | buy | 2,500 |
| Dec 15, 25 | Elam Nevan C | buy | 32,000 |
Our RZLT coverage
Recent articles, reports, and earnings notes.
No research on RZLT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RZLT report →Similar companies
Peers in the same neighborhood.